<DOC>
	<DOC>NCT02604485</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and clinical pharmacology of a single dose pharmacokinetics and pharmacodynamics of XOMA 358 in subjects with hypoglycemia associated with congenital hyperinsulinism.</brief_summary>
	<brief_title>A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism</brief_title>
	<detailed_description />
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<criteria>Clinical diagnosis of congenital hyperinsulinism Duration of glucose levels less than 70mg/dL, by CGM, for an average of at least 120 minutes a day across baseline Days 3, 2, and 1 with no single duration less than 60 minutes on any of the baseline Days 3, 2, or 1, unless the subject received rescue treatment. Can safely washout of background medications used to treat hyperinsulinism. Use of any agent, such as diazoxide, octreotide, chronic systemic glucocorticoids, or β agonists that may affect glucose metabolism Body Mass Index ≥ 35 kg/m2 Pregnant females, females planning to become pregnant during the course of the study, females who have delivered 3 months before screening, or breastfeeding Male subjects who are planning a pregnancy with a female partner during the course of the study or within 4 months after administration of study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypoglycemia</keyword>
	<keyword>Congenital Hyperinsulinism</keyword>
</DOC>